RPE tears following anti-VEGF therapy

Article

Tears of the retinal pigment epithelium (RPE) may develop during the course of anti-VEGF therapy for age-related macular degeneration (AMD) related pigment epithelial detachment (PED).

Tears of the retinal pigment epithelium (RPE) may develop during the course of anti-VEGF therapy for age-related macular degeneration (AMD) related pigment epithelial detachment (PED), according to a study published in the June issue of Retina.

Louis Chang and David Sarraf of the Jules Stein Eye Institute, University of California and Kaiser Permanente, Los Angeles, California, USA conducted a literature search of RPE tears or rips using the PubMed database. They also included a retrospective analysis of an additional five cases of RPE tears following anti-VEGF therapy, four following bevacizumab and one following ranibizumab.

A total of 33 cases of RPE tear after treatment with pegaptanib, bevacizumab and ranibizumab have previously been reported and of these, the authors collected and analysed the data from 25, in addition to the five other cases.

The common features of each of the 30 cases included: advanced age of patient, the presence of fibrovascular PED or PED associated choroidal neovascularization (CNV) and diagnosis of the tear within four to eight weeks of the first or second injection.

The authors concluded that patients with high-risk lesions, in particular large irregular PED associated with CNV, should be advised and monitored carefully for signs of RPE which could limit their visual prognosis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
© 2025 MJH Life Sciences

All rights reserved.